Cargando…
Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center
OBJECTIVE: The choice between primary debulking surgery (PDS) and neoadjuvant chemotherapy (NAC) in advanced ovarian cancer remains controversial. We evaluated NAC use in our center before and after results from a randomized trial were published, with the aim to determine the impact of changes in th...
Autores principales: | Lee, Yong Jae, Chung, Young Shin, Lee, Jung-Yun, Nam, Eun Ji, Kim, Sang Wun, Kim, Sunghoon, Kim, Young Tae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981113/ https://www.ncbi.nlm.nih.gov/pubmed/29770632 http://dx.doi.org/10.3802/jgo.2018.29.e63 |
Ejemplares similares
-
Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017) -
Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020) -
A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
por: Park, Junsik, et al.
Publicado: (2020) -
Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020) -
Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer
por: Kim, Yoo-Na, et al.
Publicado: (2019)